Development of peptide vaccines in dengue

Kavita Reginald, Yanqi Chan, Magdalena Plebanski, Chit Laa Poh

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.

Original languageEnglish
Pages (from-to)1157-1173
Number of pages17
JournalCurrent Pharmaceutical Design
Volume24
Issue number11
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Cell mediated immunity
  • Dengue
  • HLA
  • Multi-epitope
  • Peptide vaccine
  • Synthetic peptides

Cite this

Reginald, Kavita ; Chan, Yanqi ; Plebanski, Magdalena ; Poh, Chit Laa. / Development of peptide vaccines in dengue. In: Current Pharmaceutical Design. 2018 ; Vol. 24, No. 11. pp. 1157-1173.
@article{5c11671227314b11b97ba74d773ac8d6,
title = "Development of peptide vaccines in dengue",
abstract = "Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.",
keywords = "Cell mediated immunity, Dengue, HLA, Multi-epitope, Peptide vaccine, Synthetic peptides",
author = "Kavita Reginald and Yanqi Chan and Magdalena Plebanski and Poh, {Chit Laa}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1381612823666170913163904",
language = "English",
volume = "24",
pages = "1157--1173",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "11",

}

Development of peptide vaccines in dengue. / Reginald, Kavita; Chan, Yanqi; Plebanski, Magdalena; Poh, Chit Laa.

In: Current Pharmaceutical Design, Vol. 24, No. 11, 01.01.2018, p. 1157-1173.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Development of peptide vaccines in dengue

AU - Reginald, Kavita

AU - Chan, Yanqi

AU - Plebanski, Magdalena

AU - Poh, Chit Laa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.

AB - Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.

KW - Cell mediated immunity

KW - Dengue

KW - HLA

KW - Multi-epitope

KW - Peptide vaccine

KW - Synthetic peptides

UR - http://www.scopus.com/inward/record.url?scp=85049746243&partnerID=8YFLogxK

U2 - 10.2174/1381612823666170913163904

DO - 10.2174/1381612823666170913163904

M3 - Review Article

VL - 24

SP - 1157

EP - 1173

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 11

ER -